Information Provided By: 
Fly News Breaks for March 30, 2016
ACOR, SAGE, DMTX
Mar 30, 2016 | 06:26 EDT
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
News For DMTX;SAGE;ACOR From the Last 2 Days
There are no results for your query DMTX;SAGE;ACOR
